<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785288</url>
  </required_header>
  <id_info>
    <org_study_id>20163</org_study_id>
    <nct_id>NCT03785288</nct_id>
  </id_info>
  <brief_title>Vaginal Cuff Brachytherapy Fractionation Study</brief_title>
  <official_title>A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Showalter, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see the effects of two different standard of care treatments
      of endometrial cancer on sexual dysfunction. This study will compare two standard of care
      treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy (Arm 1) to
      HDR vaginal brachytherapy 6 fractions of 4Gy (Arm 2) for early stage endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to Arm 1: HDR vaginal brachytherapy 7 Gy in 3 fractions prescribed at
      5mm. Radiation delivered 4-12 weeks after surgery OR Arm 2: HDR vaginal brachytherapy 4Gy in
      6 fractions prescribed at the cylinder surface. Radiation delivered 4-12 weeks after surgery.
      Participants in both arms will receive standard vaginal dilator for use after treatment (to
      promote healing). 1 and 2 year follow up assessments are performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will compare two standard of care treatments: HDR vaginal brachytherapy 3 fractions of 7Gy (Arm 1) to HDR vaginal brachytherapy 6 fractions of 4Gy (Arm 2) for early stage endometrial cancer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>1 year</time_frame>
    <description>Using the FSFI, compare patient reported sexual dysfunction at 1 year after completion of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal Length Measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Using vaginal dilator compare patient vaginal measurement 1 year after completion of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal Length Measurement</measure>
    <time_frame>2 years</time_frame>
    <description>Using vaginal dilator compare patient vaginal measurement 2 years after completion of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>HDR VBT 3 fxs of 7Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: HDR vaginal brachytherapy 3 fractions of 7Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDR VBT 6 fxs of 4Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: HDR vaginal brachytherapy 6 fractions of 4Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR vaginal brachytherapy</intervention_name>
    <description>Arm 1: HDR vaginal brachytherapy 7 Gy in 3 fractions ; Arm 2: HDR vaginal brachytherapy 4 Gy in 6 fractions</description>
    <arm_group_label>HDR VBT 3 fxs of 7Gy</arm_group_label>
    <arm_group_label>HDR VBT 6 fxs of 4Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness and ability to provide written informed consent and to comply with the
             study protocol as judged by the investigator.

          -  Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral
             Salpingo Oophorectomy (TH-BSO) with or without lymph node dissection.

          -  Subject must have FIGO Stage I-II (grade 1-3) pathologically proven (histologic)
             endometrioid cancer, including all subtypes. Serous, clear cell, and carcinosarcoma
             histologic pathologies are allowed.

          -  Subjects must have no measurable disease after surgery.

          -  ECOG Performance Status of 0-2

          -  Age ≥ 18 years

          -  Subject must have a life expectancy ≥ 12 months

        Exclusion Criteria:

          -  Disease of more advanced stage (FIGO stage III-IV) or disease for which adjuvant
             external beam radiation therapy or chemotherapy is indicated

          -  Patients with history of prior pelvic radiation therapy or if additional pelvic
             radiation therapy is planned

          -  Subjects who have not recovered from side effects of agents administered more than 4
             weeks prior to on-study date

          -  Subjects that require &gt; 14 weeks between surgery and initiation of radiotherapy on
             study

          -  Subjects who are receiving any investigational agents or have had any investigational
             agent within the 30 days prior to on-study date

          -  Subject is unable or unwilling to participate in a study related procedure

          -  Pregnant and breastfeeding women are excluded from this study

          -  Subject is a prisoner

          -  A serious uncontrolled medical disorder that in the opinion of the Investigator would
             impair the ability of the subject to receive protocol therapy.-Subjects with history
             of evidence upon physical examination of central nervous system disease including
             primary brain tumor, seizures not controlled with standard medical therapy, any brain
             metastases, or history of cerebrovascular accident (stroke), transient ischemic
             attack, or subarachnoid hemorrhage within six months of study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Showalter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April Muniz, MSHS,CCRA</last_name>
    <phone>434-243-5350</phone>
    <phone_ext>3-5350</phone_ext>
    <email>am4pf@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Britnee Ochabski</last_name>
    <phone>(434) 924-9969</phone>
    <email>BLO4E@hscmail.mcc.virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland Medical Center (UMMC)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ermiece Straub</last_name>
      <phone>410-328-8018</phone>
      <email>ermiece.straub@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Eggleston</last_name>
      <phone>410-328-7586</phone>
      <email>caitlineggleston@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pranshu Mohindra, MD, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Nichols, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack J Hong, MD, FACRO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sally Cheston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Showalter, MD</last_name>
      <email>TNS3B@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Smith</last_name>
      <email>AJB6BB@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kara Romano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Showalter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leigh Cantrell, MD, MSPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Timothy Showalter, MD</investigator_full_name>
    <investigator_title>Principle Investigator-MD Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

